NASDAQ:VCNX Vaccinex Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vaccinex Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.81 -0.05 (-2.69 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$1.70Now: $1.81▼$1.8550-Day Range$1.86MA: $5.34▼$6.7652-Week Range$1.70Now: $1.81▼$12.23Volume1.29 million shsAverage Volume351,711 shsMarket Capitalization$36.37 millionP/E RatioN/ADividend YieldN/ABeta1.48 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy; BVX20, an investigational and humanized monoclonal antibody for the treatment of for multiple sclerosis. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingVaccinex has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.00, Vaccinex has a forecasted upside of 1,115.5% from its current price of $1.81.Amount of Analyst CoverageVaccinex has only been the subject of 2 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesVaccinex has received 114 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVaccinex has received 158 “underperform” votes. (Add your “underperform” vote.)Community SentimentVaccinex has received 58.09% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vaccinex and other stocks. Vote “Outperform” if you believe VCNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VCNX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVaccinex does not currently pay a dividend.Dividend GrowthVaccinex does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaccinex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,999,998.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders68.60% of the stock of Vaccinex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.87% of the stock of Vaccinex is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vaccinex are expected to decrease in the coming year, from ($1.75) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaccinex is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaccinex is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.3Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.87 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VCNX Previous Symbol CUSIPN/A CIKN/A Webwww.vaccinex.com Phone585-271-2700Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick Ratio0.34Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$520,000.00 Price / Sales69.94 Cash FlowN/A Price / Cash FlowN/A Book Value($0.15) per share Price / Book-12.07Profitability EPS (Most Recent Fiscal Year)($2.47) Net Income$-31,860,000.00 Net MarginsN/A Return on Equity-2,277.96% Return on Assets-472.22%Miscellaneous Employees44 Outstanding Shares20,094,000Market Cap$36.37 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $1.81 -0.05 (-2.69 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VCNX News and Ratings via Email Sign-up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter. Vaccinex (NASDAQ:VCNX) Frequently Asked Questions How has Vaccinex's stock price been impacted by Coronavirus (COVID-19)? Vaccinex's stock was trading at $4.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VCNX stock has decreased by 56.6% and is now trading at $1.81. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Vaccinex? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaccinex. When is Vaccinex's next earnings date? Vaccinex is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Vaccinex. How were Vaccinex's earnings last quarter? Vaccinex Inc (NASDAQ:VCNX) released its earnings results on Friday, August, 14th. The company reported ($0.39) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.51) by $0.12. View Vaccinex's earnings history. What price target have analysts set for VCNX? 2 Wall Street analysts have issued 1-year price objectives for Vaccinex's stock. Their forecasts range from $22.00 to $22.00. On average, they anticipate Vaccinex's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 1,115.5% from the stock's current price. View analysts' price targets for Vaccinex. Are investors shorting Vaccinex? Vaccinex saw a increase in short interest in August. As of August 31st, there was short interest totaling 52,200 shares, an increase of 27.3% from the August 15th total of 41,000 shares. Based on an average daily volume of 566,200 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.8% of the company's shares are short sold. View Vaccinex's Short Interest. Who are some of Vaccinex's key competitors? Some companies that are related to Vaccinex include Aytu Bioscience (AYTU), Galectin Therapeutics (GALT), Sesen Bio (SESN), ContraFect (CFRX), Harrow Health (HROW), Pivot Pharmaceuticals (PVOTF), AcelRx Pharmaceuticals (ACRX), BELLUS Health (BLU), CELYAD SA/ADR (CYAD), Corbus Pharmaceuticals (CRBP), Minerva Neurosciences (NERV), vTv Therapeutics (VTVT), Evolus (EOLS), Adamas Pharmaceuticals (ADMS) and Genprex (GNPX). View all competitors. What other stocks do shareholders of Vaccinex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), Opko Health (OPK), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Heat Biologics (HTBX), AbbVie (ABBV) and AVEO Pharmaceuticals (AVEO). Who are Vaccinex's key executives? Vaccinex's management team includes the following people: Dr. Maurice Zauderer, Co-Founder, CEO, Pres & Director (Age 73)Mr. Raymond E. Watkins, Sr. VP & COO (Age 61)Dr. Ernest S. Smith, Sr. VP of Research & Chief Scientific Officer (Age 47)Dr. Deepak M. Sahasrabudhe, Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical AdvisorMr. Scott E. Royer C.F.A., M.B.A., Chief Financial Officer (Age 45) When did Vaccinex IPO? (VCNX) raised $45 million in an initial public offering on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager. What is Vaccinex's stock symbol? Vaccinex trades on the NASDAQ under the ticker symbol "VCNX." How do I buy shares of Vaccinex? Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Vaccinex's stock price today? One share of VCNX stock can currently be purchased for approximately $1.81. How big of a company is Vaccinex? Vaccinex has a market capitalization of $36.37 million and generates $520,000.00 in revenue each year. The company earns $-31,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Vaccinex employs 44 workers across the globe. What is Vaccinex's official website? The official website for Vaccinex is www.vaccinex.com. How can I contact Vaccinex? Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
